Table 1. Patient and donor characteristics and apheresis results.
| Patient and donor characteristics (n = 72) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Age at PBSCH (median, range) | 54 (21–68) years | ||||||||
| Male/female | 41/31 | ||||||||
| Healthy donor | 22 | ||||||||
| Malignant lymphoma | 35 | ||||||||
| Plasma cell neoplasm | 15 | ||||||||
| Apheresis results (n = 118) | |||||||||
| From healthy donor | 36 | ||||||||
| patient with malignant lymphoma | 53 | ||||||||
| patient with plasma cell neoplasm | 29 | ||||||||
| Course of PBSCH First course | 102 | ||||||||
| Second course | 16 | ||||||||
| PBSCH days Day 1 | 70 | ||||||||
| Day 2 | 43 | ||||||||
| Day 3 | 5 | ||||||||
| Median number (range) of CD34+ cells/kg | |||||||||
| All case | Healthy donors | Patients with ML and PCN | |||||||
| CD34+ cells/kg collected via apheresis (× 106/kg) (n=118) | 1.29 (0.03–22.80) | 1.30 (0.13–11.3) | 1.21 (0.03–22.8) | ||||||
| Total CD34+ cells/kg in a course of PBSCH (× 106/kg) (n=72) | 2.53 (0.13–22.8) | 2.63 (0.75–12.4) | 2.50 (0.13–22.8) | ||||||
| Median counts (range) for the laboratory data in the PB on harvest day | |||||||||
| All case | Healthy donors | Patients with ML and PCN | |||||||
| WBC (× 103/µL) | 19.25 (5–64.0) | 43.4 (22.4–64.0) | 10.6 (5–47.8) | ||||||
| Myeloblast (/µL) | 0 (0–860) | 0 (0–191.5) | 0 (0–860) | ||||||
| Platelets (× 104/µL) | 9.8 (1.6–30.9) | 18.5 (9.3–30.9) | 6.7 (1.6–24.7) | ||||||
| HPC (/µL) | 25 (0–899) | 29 (0-162) | 23.5 (0–899) | ||||||
ML, malignant lymphoma; PCN, plasma cell neoplasm; PBSCH, peripheral blood stem cell harvest; WBC, white blood cell; HPC, hematopoietic progenitor cell.